MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Cardium Therapeutics, Inc. (CXM) Presentation Summarizes Platforms And Strategy 0 comments
    Jan 10, 2013 3:02 PM | about stocks: CXM

    When health sciences and regenerative medicine company Cardium Therapeutics made their presentation recently at the Biotech Showcase Conference in San Francisco, they summarized their unique collection of technology platforms, detailing respective market potential and plans for the future for associated products, including prospects under their umbrella covering Genedexa, LifeAgain, and To Go Brands.

    • Tissue Engineering Platform (Formulated collagen and DNA-activated matrices for wound and orthopedic repair) - Excellagen and its first product extension Genedexa are for the treatment of wound tissue. Excellagen is a collagen gel used to promote the healing of many types of wounds. Genedexa is focused initially on the treatment of chronic, non-healing diabetic foot ulcers.

    • Cardiovascular Growth Factor Biologics Platform (Portfolio acquired from Schering AG) - Generx is an interventional cardiology-focused product candidate that facilitates blood vessel formation in patients with Cardiac Microvascular Insufficiency (NYSE:CMI).

    • Health Sciences Platform (Organic mixes, nutraceuticals, dietary supplements) - MedPodium, together with recently acquired To Go Brands to support logistical infrastructure, represent a comprehensive set of science-based lifestyle solutions.

    • Medical Analytics Platform (E-commerce platform of algorithms and medical-based social media programs supporting life insurance underwriting for patients dealing with cancer and chronic medical diseases) - LifeAgain offers life insurance for cancer survivors.

    Cardium also presented investment highlights, showing the status and strategy for each of the product areas, and stressing the company's focus on its capital-efficient, asset-based business strategy, designed to provide a diversified and balanced portfolio of risk/return opportunities:

    • FDA 510(k) clearance for U.S. marketing and sales, with international CE mark registration targeted for Q1 of 2013
    • Strategic partnering process underway, with recently announced marketing and sales agreement with Academy Medical for U.S. Government installations

    • International cost-efficient "ASPIRE" Phase 3 / Registration Study underway

    • Recently announced acquisition of To Go Brands to support logistical infrastructure to accelerate revenue

    Cardium Werks
    • Partner-enabled platform opportunities, with the possibility of independent financing strategies being utilized

    The key take-away for investors is that Cardium has no outstanding debt and substantial trading liquidity, with continuing news flow expected from product platforms and other opportunities under consideration. The company's current capital structure provides for significant economic upside potential as CXM executes its asset-based business strategy.

    For more information on Cardium, visit www.CardiumTHX.com

    Sign up for "The Mission Report" at www.MissionIR.com

    Stocks: CXM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.